Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

B-Cell Acute Lymphoblastic Leukemia: Donor Matters in Allogeneic Stem Cell Transplant Outcomes of Hispanic Patients

Karam Ashouri, Brian Hom, Mollee Chu, Jennifer Hwang, Karen Resnick, Yekta Rahimi, Robert Ireland, Anush Aram Ginosyan, Eljie Isaak Bragasin, Preet M. Chaudhary, Karrune Woan, Imran Siddiqi, Abdullah Ladha, Amir Ali, George Yaghmour

Blood (2023) 142 (Supplement 1): 2241.

https://doi.org/10.1182/blood-2023-190541

Published: 2023

Journal Articles

Philadelphia-like B-Cell Acute Lymphoblastic Leukemia in a Largely Hispanic Population: Disease Features and Outcomes in the Era of Immunotherapy a Single Institutional Study

Blood (2023) 142 (Supplement 1): 4208.

https://doi.org/10.1182/blood-2023-190716

Published: 2023

Journal Articles

Outcomes of Myelofibrosis Patients in the Era of Using JAK2 Inhibitor with Allogeneic-HSCT at the University of Southern California

Vincent Louie Louie Mendiola, Krithika Chennapan, Denaly Chen, Jack Rodman, Amir Ali, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2022) 140 (Supplement 1): 12256–12258.

https://doi.org/10.1182/blood-2022-164745

Published: 2022

Journal Articles

Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study

Krithika Chennapan, Karam Ashouri, Anastasia Martynova, Samvel Nazaretyan, Amir Ali, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, Imran Siddiqi, George Yaghmour

Blood (2022) 140 (Supplement 1): 4823–4824.

https://doi.org/10.1182/blood-2022-163658

Published: 2022

Journal Articles

First Reported Evaluation of Outcomes and Safety of Using "Flipped" Conditioning Regimens of Fractionated Total Body Irradiation Followed By Fludarabine Vs Cyclophosphamide for Allogeneic-Hematopoietic Stem Cell Transplant at the University of Southern California

Vincent Louie Louie Mendiola, Denaly Chen, Jack Rodman, Amir Ali, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2022) 140 (Supplement 1): 12821–12823.

https://doi.org/10.1182/blood-2022-164771

Published: 2022

Journal Articles

Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy

Lydia D Chow, Denaly Chen, Maria E. Vergara-Lluri, Eric Tam, Karrune Woan, Preet M. Chaudhary, George Yaghmour, Abdullah Ladha

Blood (2022) 140 (Supplement 1): 9027–9028.

https://doi.org/10.1182/blood-2022-171127

Published: 2022

Journal Articles

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Vincent Louie Louie Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11702–11704.

https://doi.org/10.1182/blood-2022-164836

Published: 2022

Journal Articles

Updated Comparison of Outcomes in Hispanic and Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen in the Era of Novel Agents

Vincent Louie Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11685–11687.

https://doi.org/10.1182/blood-2022-167684

Published: 2022

Journal Articles

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Vincent Louie Ramos Mendiola, Catherine Ly, Jennifer Wang, Thuy Bui, Jack Rodman, Amir Ali, Maria E. Vergara-Lluri, Karrune Woan, Eric Tam, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2022) 140 (Supplement 1): 11668–11670.

https://doi.org/10.1182/blood-2022-167512

Published: 2022

Journal Articles

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 4372.

https://doi.org/10.1182/blood-2021-150135

Published: 2021

Journal Articles

Evaluating Outcomes Using Post-Transplant Cyclophosphamide/Tacrolimus/Mycophenolate Mofetil As Gvhd Prophylaxis Compared with Methotrexate/Tacrolimus in Matched-Related and Matched-Unrelated Hematopoietic Stem Cell Transplant in Relation to the Haploidentical Setting in Acute Lymphoblastic Leukemia: A Single Center Experience

Sami Dwabe, Hugo Martinez, Jack Rodman, Eric Tam, Abdullah Ladha, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2021) 138 (Supplement 1): 4874.

https://doi.org/10.1182/blood-2021-149165

Published: 2021

Journal Articles

Outcomes of COVID-19 in Hematopoietic Stem-Cell Transplant Recipients: A Single Institution Observational Study

Sami Dwabe, Lakshmi Savitala-Damerla, Jack Rodman, Abdullah Ladha, Eric Tam, Houda Alachkar, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2021) 138 (Supplement 1): 4896.

https://doi.org/10.1182/blood-2021-149204

Published: 2021

Journal Articles

An Update on Outcomes Using the USC ALL Frontline Regimen (based on CCG-1882) after Further Modification of Protocol in the Era of Novel Agents in Ph-Negative ALL Patients; A Retrospective Study

Vincent Louie Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Maria E. Vergara-Lluri, Karrune Woan, Eric Tam, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 3362.

https://doi.org/10.1182/blood-2021-147124

Published: 2021

Journal Articles

Superior Outcomes in Hispanic Patients Compared to Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen for Newly Diagnosed ALL Patients in the Era of Novel Agents; A Retrospective Study

Vincent Louie Ramos Mendiola, Catherine Ly, Thuy Bui, Jennifer Wang, Jack Rodman, Karrune Woan, Eric Tam, Maria E. Vergara-Lluri, Preet M. Chaudhary, Dan Douer, Abdullah Ladha, George Yaghmour

Blood (2021) 138 (Supplement 1): 3361.

https://doi.org/10.1182/blood-2021-150116

Published: 2021

Journal Articles

Updated Outcomes during the Pandemic: Relationship between CD34and CD3 Cell Doses, One-Year Graft-Versus-Relapse-Free-Survival, Graft-Versus-Host Disease, and Overall Survival in Haploidentical Hematopoietic Stem Cell Transplantation Using Post Transplant Cytoxan: A Single Center Experience

Anastasia Martynova, Krithika Chennapan, Jack Rodman, Mindy Hsiao, Abdullah Ladha, Eric Tam, Karrune Woan, Preet M. Chaudhary, George Yaghmour

Blood (2021) 138 (Supplement 1): 1773.

https://doi.org/10.1182/blood-2021-152625

Published: 2021

Journal Articles

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

Frank Cichocki, PhD, Ryan Bjordahl, PhD, Karrune Woan, MD PhD, Zachary Davis, PhD BS, Greg Bonello, Sajid Mahmood, PhD, Paul Rogers, PhD, Moyar Q. Ge, PhD, Tom Lee, PhD, Martin Felices, PhD, Bruce Walcheck, PhD, Bruce R. Blazar, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2020) 136 (Supplement 1): 57–58.

https://doi.org/10.1182/blood-2020-137138

Published: 2020

Journal Articles

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

Ryan Bjordahl, PhD, Svetlana Gaidarova, MS, Karrune Woan, MD PhD, Frank Cichocki, PhD, Greg Bonello, PhD, Megan Robinson, Chelsea Ruller, Mochtar Pribadi, PhD, Jason Dinella, PhD, Lauren Fong, PhD, Janel Huffman, MS, Hui-yi Chu, PhD, Tom Lee, PhD, Ramzey Abujarour, PhD, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Jeffrey S. Miller, MD, Bahram Valamehr, PhD

Blood (2019) 134 (Supplement_1): 133.

https://doi.org/10.1182/blood-2019-131138

Published: 2019

Journal Articles

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

Frank Cichocki, PhD, Karrune Woan, MD PhD, Cheng-Ying Wu, Bruce R. Blazar, MD, Ryan Bjordahl, PhD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2019) 134 (Supplement_1): 3215.

https://doi.org/10.1182/blood-2019-124490

Published: 2019

Journal Articles

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Karrune Woan, MD PhD, Ryan Bjordahl, PhD, Frank Cichocki, PhD, Svetlana Gaidarova, MS, Cameron Pride, BS, Dan S Kaufman, MD PhD, Karl-Johan Malmberg, MD PhD, Sarah Cooley, MD, Bahram Valamehr, PhD, Jeffrey S. Miller, MD

Blood (2018) 132 (Supplement 1): 3224.

https://doi.org/10.1182/blood-2018-99-116459

Published: 2018

Journal Articles

Identification of a Discrete Subpopulation of T-Cells Over-Expressing HDAC11 with a TH17 Phenotype

Karrune Woan, Fengdong Cheng, Hongwei Wang, Jennifer Rock-Klotz, Zi Wang, Yu Yu, Edward Seto, Noreen Luetteke, Xue-Zhong Yu, Alejandro Villagra, Eduardo M. Sotomayor, MD

Blood (2010) 116 (21): 588.

https://doi.org/10.1182/blood.V116.21.588.588

Published: 2010

NARROW

B-Cell Acute Lymphoblastic Leukemia: Donor Matters in Allogeneic Stem Cell Transplant Outcomes of Hispanic Patients

Philadelphia-like B-Cell Acute Lymphoblastic Leukemia in a Largely Hispanic Population: Disease Features and Outcomes in the Era of Immunotherapy a Single Institutional Study

Outcomes of Myelofibrosis Patients in the Era of Using JAK2 Inhibitor with Allogeneic-HSCT at the University of Southern California

Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study

First Reported Evaluation of Outcomes and Safety of Using "Flipped" Conditioning Regimens of Fractionated Total Body Irradiation Followed By Fludarabine Vs Cyclophosphamide for Allogeneic-Hematopoietic Stem Cell Transplant at the University of Southern California

Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy

Updated Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Peg-Asparaginase in the Era of Novel Agents

Updated Comparison of Outcomes in Hispanic and Non-Hispanic Patients with Ph-Negative Acute Lymphoblastic Leukemia Using the Modified Pediatric-Based University of Southern California Acute Lymphoblastic Leukemia (USC ALL) Regimen in the Era of Novel Agents

Updated Outcomes of the University of Southern California (USC) ALL Frontline Regimen (based on CCG-1882) after Protocol Modification in the Era of Novel Agents in Ph-Negative ALL Patients

Outcomes in Adult Philadelphia-Positive Acute Lymphoblastic Leukemia Patients Using Tyrosine Kinase Inhibitors Combined with the Modified University of Southern California (USC ALL) Regimen without Pegaspargase in the Era of Novel Agents; A Retrospective Study

Outcomes of COVID-19 in Hematopoietic Stem-Cell Transplant Recipients: A Single Institution Observational Study

An Update on Outcomes Using the USC ALL Frontline Regimen (based on CCG-1882) after Further Modification of Protocol in the Era of Novel Agents in Ph-Negative ALL Patients; A Retrospective Study

Updated Outcomes during the Pandemic: Relationship between CD34and CD3 Cell Doses, One-Year Graft-Versus-Relapse-Free-Survival, Graft-Versus-Host Disease, and Overall Survival in Haploidentical Hematopoietic Stem Cell Transplantation Using Post Transplant Cytoxan: A Single Center Experience

Triple Gene-Modified iPSC-Derived NK Cells Combined with Daratumumab for Targeted Immunotherapy Against AML

FT538: Preclinical Development of an Off-the-Shelf Adoptive NK Cell Immunotherapy with Targeted Disruption of CD38 to Prevent Anti-CD38 Antibody-Mediated Fratricide and Enhance ADCC in Multiple Myeloma When Combined with Daratumumab

NK Cells Lacking CD38 Are Resistant to Oxidative Stress-Induced Death

CD38-Deficient, CD16-Engineered NK Cells Exhibit Enhanced Antibody-Dependent Cellular Cytotoxicity without NK Cell Fratricide to Augment Anti-Myeloma Immunity in Combination with Daratumumab

Identification of a Discrete Subpopulation of T-Cells Over-Expressing HDAC11 with a TH17 Phenotype

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only